http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GE-P20053688-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2001-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb1c3f7457c8c783cba3b6d4e26e6cf9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77de3409afd6623e368707b858b5b755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cba8bf567c2a8e13c7ddf6f75dd6b752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87ebd9d09940bc052376ed0ba36db995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a09ab5d6f3328130449620f553bc57b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b067f4496959ee0b428c7d49629593c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af2c217a26906b553091825b11ade901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe9ee14a3cb91187e75b4d0ac24994bb
publicationDate 2005-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GE-P20053688-B
titleOfInvention Substituted-Triazolopyrimidines as Anticancer Agents
abstract 1. Technical Result Enhancement of medicinal properties. 2. Essence Use of a substituted triazolopyrimidine derivative of formula (1) (values R1, R2, R3, and R4 are provided in the description) and pharmaceutically acceptable salts thereof for treating of the growth of cancerous tumour cells and associated diseases or for inhibiting thereof in a mammals. 3. Field of Application Medicine.
priorityDate 2000-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481482
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5327131

Total number of triples: 32.